UK's ABHI gets a say in NHS procurement shake-up
This article was originally published in Clinica
Executive Summary
The UK medical technology industry has secured a hard-fought consultative role in the far-reaching reforms of healthcare product procurement in the NHS. The Department of Health today issued a call for evidence and a new date for the publication of a definitive strategy in this area, while unveiling “for immediate implementation” a series of procurement standards and guidelines.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.